Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients WithALK-Rearranged Non–Small-Cell Lung Cancer: A Retrospective Analysis

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Second-generation anaplastic lymphoma kinase (ALK) inhibitors, such as alectinib and ceritinib, have recently been approved for treatment of ALK-rearranged non–small-cell lung cancer (NSCLC). An optimal strategy for using 2 or more ALK inhibitors has not been established. We sought to investigate the clinical impact of sequential use of ALK inhibitors on these tumors in clinical practice.

Patients and Methods

Patients with ALK-rearranged NSCLC treated from May 2010 to January 2016 at the National Cancer Center Hospital were identified, and their outcomes were evaluated retrospectively.

Results

Fifty-nine patients with ALK-rearranged NSCLC had been treated and 37 cases were assessable. Twenty-six received crizotinib, 21 received alectinib, and 13 (35.1%) received crizotinib followed by alectinib. Response rates and median progression-free survival (PFS) on crizotinib and alectinib (after crizotinib failure) were 53.8% (95% confidence interval [CI], 26.7%-80.9%) and 38.4% (95% CI, 12.0%-64.9%), and 10.7 (95% CI, 5.3-14.7) months and 16.6 (95% CI, 2.9-not calculable), respectively. The median PFS of patients on sequential therapy was 35.2 months (95% CI, 12.7 months-not calculable). The 5-year survival rate of ALK-rearranged patients who received 2 sequential ALK inhibitors from diagnosis was 77.8% (95% CI, 36.5%-94.0%).

Conclusion

The combined PFS and 5-year survival rates in patients who received sequential ALK inhibitors were encouraging. Making full use of multiple ALK inhibitors might be important to prolonging survival in patients with ALK-rearranged NSCLC.

Micro-Abstract

Sequential anaplastic lymphoma kinase (ALK) inhibitors for ALK-rearranged non–small-cell lung cancer (NSCLC) in Japanese patients were retrospectively reviewed. Thirteen patients received crizotinib followed by alectinib. The combined median progression-free survival and 5-year survival rates of patients who received sequential ALK inhibitors were 35.2 months and 77.8%. Making full use of multiple ALK inhibitors might be important to prolonging survival in patients with ALK-rearranged NSCLC.

Related Topics

    loading  Loading Related Articles